Skip to Main Content

Author Details

Coert J Zuurbier
University Medical Centers
1991
116
40
PMIDPaper TitleJournal TitlePublished Year
38061206Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis.Redox Biol2024
36649392Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.Circulation2023
37565139Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.Front Physiol2023
37408266Pharmacological Cardioprotection against Ischemia Reperfusion Injury-The Search for a Clinical Effective Therapy.Cells2023
36753049Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacol Rev2023
36623448Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells.Biomed Pharmacother2023
36718529Cardioprotective efficacy of limb remote ischaemic preconditioning in rats: discrepancy between a meta-analysis and a three-centre in vivo study.Cardiovasc Res2023
34896968Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na<sup>+</sup>]<sub>c</sub>/ROS-pathway in human endothelial cells.Biomed Pharmacother2022
35581445Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?Basic Res Cardiol2022
35393687Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection.Br J Pharmacol2022
35894858Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.Eur Heart J Cardiovasc Pharmacother2022
35331696Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.J Mol Cell Cardiol2022
35303888Direct cardiac effects of SGLT2 inhibitors.Cardiovasc Diabetol2022
32295413Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress.Antioxid Redox Signal2021
33792689Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.Cardiovasc Res2021
33569824Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy.J Magn Reson Imaging2021
33484825Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury.Free Radic Biol Med2021
33588049Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling.Free Radic Biol Med2021
33914182The Redox Modulating Sonlicromanol Active Metabolite KH176m and the Antioxidant MPG Protect Against Short-Duration Cardiac Ischemia-Reperfusion Injury.Cardiovasc Drugs Ther2021
34527711Cardioprotecive Properties of Known Agents in Rat Ischemia-Reperfusion Model Under Clinically Relevant Conditions: Only the NAD Precursor Nicotinamide Riboside Reduces Infarct Size in Presence of Fentanyl, Midazolam and Cangrelor, but Not Propofol.Front Cardiovasc Med2021
34205045Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.Int J Mol Sci2021
33048256Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.Cardiovasc Drugs Ther2021
32194159SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.Biochim Biophys Acta Mol Basis Dis2020
31985828Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.Br J Pharmacol2020
33344518Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.Front Cardiovasc Med2020
33362773NLRX1 Deletion Increases Ischemia-Reperfusion Damage and Activates Glucose Metabolism in Mouse Heart.Front Immunol2020
32950054Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?Cardiovasc Diabetol2020
32384583Cardiac metabolism as a driver and therapeutic target of myocardial infarction.J Cell Mol Med2020
32562699Targeting metabolic pathways to treat cardiovascular diseases.Biochim Biophys Acta Mol Basis Dis2020
30649212Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.Cardiovasc Res2019
31724838Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.Cell Physiol Biochem2019
31697425Volume incompliance and transfusion are essential for transfusion-associated circulatory overload: a novel animal model.Transfusion2019
31356546NLRP3 Inflammasome in Cardioprotective Signaling.J Cardiovasc Pharmacol2019
31425237Ketamine-(Dex)Medetomidine, Hyperglycemia, Glycocalyx, and Vascular Permeability.Anesth Analg2019
30941055Editorial: Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches.Front Physiol2019
30576455Innate immunity as a target for acute cardioprotection.Cardiovasc Res2019
30461025Washing or filtering of blood products does not improve outcome in a rat model of trauma and multiple transfusion.Transfusion2019
29159800Effects of combined helium pre/post-conditioning on the brain and heart in a rat resuscitation model.Acta Anaesthesiol Scand2018
30519189Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.Front Physiol2018
29555979Helium alters the cytoskeleton and decreases permeability in endothelial cells cultured in vitro through a pathway involving Caveolin-1.Sci Rep2018
29635338Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B.Cardiovasc Res2018
29514047Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome.Biochim Biophys Acta Mol Basis Dis2018
29600031Remote ischaemic preconditioning of the lung: from bench to bedside-are we there yet?J Thorac Dis2018
29283977Divergent Effects of Hypertonic Fluid Resuscitation on Renal Pathophysiological and Structural Parameters in Rat Model of Lower Body Ischemia/Reperfusion-Induced Sterile Inflammation.Shock2018
29197997Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na<sup>+</sup>/H<sup>+</sup> exchanger, lowering of cytosolic Na<sup>+</sup> and vasodilation.Diabetologia2018
27752710Empagliflozin decreases myocardial cytoplasmic Na<sup>+</sup> through inhibition of the cardiac Na<sup>+</sup>/H<sup>+</sup> exchanger in rats and rabbits.Diabetologia2017
28356068A randomized trial of remote ischemic preconditioning and control treatment for cardioprotection in sevoflurane-anesthetized CABG patients.BMC Anesthesiol2017
28986541Cyclophilin D ablation is associated with increased end-ischemic mitochondrial hexokinase activity.Sci Rep2017
28626071NLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity.J Exp Med2017
28641785Acute detachment of hexokinase II from mitochondria modestly increases oxygen consumption of the intact mouse heart.Metabolism2017
  • 1 - 50 of 116

Recommended Authors

Wenjun Yan
The First Affiliated Hospital of Zhengzhou University
Career Start Year 2009
Number of shared co-authors 0
Quan Cao
Renmin Hospital of Wuhan University
Career Start Year 2007
Number of shared co-authors 0
Christopher Lotz
University Hospital Wuerzburg
Career Start Year 2007
Number of shared co-authors 0
Quintin J Quinones
Mayo Clinic in Florida
Career Start Year 2006
Number of shared co-authors 0
Aslan T Turer
University of Texas Southwestern Medical Center Dallas TX USA.
Career Start Year 2005
Number of shared co-authors 0
Stefan Brunner
Klinikum der Universitat Munchen
Career Start Year 2005
Number of shared co-authors 0
Li Zhang
Brigham and Women's Hospital and Harvard Medical School
Career Start Year 2003
Number of shared co-authors 0
Iwan C C van der Horst
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University
Career Start Year 2001
Number of shared co-authors 2
David A Liem
University of California davis
Career Start Year 2001
Number of shared co-authors 0
Mohit Jain
Cumming School of Medicine, University of Calgary, 0 Hospital Drive NW
Career Start Year 2000
Number of shared co-authors 0
Junbo Ge
Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
Career Start Year 1999
Number of shared co-authors 0
Julie R McMullen
Baker Heart and Diabetes Institute
Career Start Year 1998
Number of shared co-authors 0
Matthias L Riess
Vanderbilt University Medical Center, 1211 Medical Center Drive
Career Start Year 1997
Number of shared co-authors 0
Peter M Kang
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 1993
Number of shared co-authors 0
Peipei Ping
University of California at Los Angeles
Career Start Year 1992
Number of shared co-authors 0
Nilanjana Maulik
University of Connecticut Health
Career Start Year 1992
Number of shared co-authors 0
Jennifer L Hall
Institute for Precision Cardiovascular Medicine
Career Start Year 1992
Number of shared co-authors 0
Jianyi Zhang
University of Alabama at Birmingham, 1670 University Boulevard
Career Start Year 1989
Number of shared co-authors 0
Tetsuya Yoshida
Hokushin General Hospital
Career Start Year 1988
Number of shared co-authors 0
Burkert Pieske
Charite University Medicine, Berlin Institute of Health (BIH)
Career Start Year 1988
Number of shared co-authors 0
Kenneth B Margulies
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 1988
Number of shared co-authors 0
Shawn W Robinson
University of Maryland
Career Start Year 1986
Number of shared co-authors 0
Serge Masson
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Career Start Year 1986
Number of shared co-authors 0
Douglas B Sawyer
Center for Molecular Medicine, Maine Medical Center Research Institute
Career Start Year 1985
Number of shared co-authors 0
Michael A Portman
Seattle Children's Hospital
Career Start Year 1982
Number of shared co-authors 0
Steven R Houser
Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University
Career Start Year 1979
Number of shared co-authors 0
Georg Ertl
University Hospital Wurzburg
Career Start Year 1974
Number of shared co-authors 0
Dimitrios Th Kremastinos
National and Kapodistrian University of Athens
Career Start Year 1973
Number of shared co-authors 0
Dipak K Das
S.N. Bose National Centre for Basic Sciences
Career Start Year 1970
Number of shared co-authors 0
Richard M Engelman
University of Massachusetts Medical School-Baystate
Career Start Year 1954
Number of shared co-authors 0

Collaborators

Nina C Weber
University Medical Centers
Co-authored papers 29
Johannes H G M van Beek
Co-authored papers 7
Markku Laakso
Co-authored papers 6
Sander M Houten
Co-authored papers 6
Nicole P Juffermans
Erasmus University Medical Center
Co-authored papers 5
Joris J T H Roelofs
University of Amsterdam
Co-authored papers 3
Hossein Ardehali
Co-authored papers 2
Marcus J Schultz
Amsterdam University Medical Centers
Co-authored papers 2
Jennifer A Muszynski
0Nationwide Children's Hospital
Co-authored papers 1
Alexander P J Vlaar
University of Amsterdam
Co-authored papers 1
Marieke J H Coenen
Co-authored papers 1
J Carel Goslings
Academic Medical Center (AMC), University of Amsterdam (UvA)
Co-authored papers 1
Mathijs R Wirtz
Amsterdam University Medical Centres
Co-authored papers 1
Philip C Spinella
Pittsburgh University
Co-authored papers 1
Peter Pickkers
Radboud University Medical Centre
Co-authored papers 1
Anthonius de Boer
Co-authored papers 1
James M Downey
Co-authored papers 1
Gerhard Liebisch
Co-authored papers 1
Fabio Di Lisa
Co-authored papers 1
Jordy Jurgens
Academic Medical Center
Co-authored papers 1
Bernard J Gersh
Mayo Clinic College of Medicine and Science
Co-authored papers 1
Gerd Heusch
Co-authored papers 1
S Matthijs Boekholdt
Co-authored papers 1
Release 1.2